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ABSTRACT
We compiled sequences of previously published
aberrant 30 splice sites (30ss) that were generated by
mutations in human disease genes. Cryptic 30ss,
defined here as those resulting from a mutation of
the 30YAG consensus, were more frequent in exons
than in introns. They clustered in  20 nt region adja-
cent to authentic 30ss, suggesting that their under-
representation in introns is due to a depletion of AG
dinucleotides in the polypyrimidine tract (PPT). In
contrast, most aberrant 30ss that were induced by
mutations outside the 30YAG consensus (designated
‘de novo’) were in introns. The activation of intronic
de novo 30ss was largely due to AG-creating muta-
tionsinthePPT.Incontrast,exonicdenovo30sswere
more often induced by mutations improving the PPT,
branchpoint sequence (BPS) or distant auxiliary sig-
nals, rather than by direct AG creation. The Shapiro–
Senapathymatrixscoreshadagoodprognosticvalue
for cryptic, but not de novo 30ss. Finally, AG-creating
mutations in the PPT that produced aberrant 30ss
upstreamofthepredictedBPSinvivosharedasimilar
‘BPS-new AG’ distance. Reduction of this distance
and/or the strength of the new AG PPT in splicing
reporter pre-mRNAsimproved utilizationofauthentic
30ss, suggesting that AG-creating mutations that are
locatedclosertotheBPSandareprecededbyweaker
PPT may result in less severe splicing defects.
INTRODUCTION
The production of mature RNA in eukaryotes requires an
accurate removal of intervening sequences or introns by splic-
ing. Splicing of precursor (pre-)mRNA is facilitated by a large
complex of small nuclear ribonucleoprotein particles (U1, U2,
U4/U6 and U5 snRNPs) and a number of non-snRNP proteins
that assemble on primary transcripts in a step-wise manner
[reviewed in (1)]. Assembly of spliceosomal complexes
requires the presence of conserved recognition sequences
in the pre-mRNA: 50 splice site (50 ss; consensus MAG/
GURAGU; M is A or C; R is purine), 30 splice site (30ss;
consensus YAG/R; Y is pyrimidine), branchpoint sequence
(BPS; mammalian consensus YNCURAY) and polypyrimi-
dine tract (PPT). In addition to these signals, efﬁcient intron
removal often entails auxiliary sequences that repress or acti-
vate splicing, termed splicing silencers or enhancers, which
function as binding sites for numerous factors, such as serine/
arginine-rich (SR) proteins (2–5). Alterations in any of these
cis-elements by mutations may severely impair pre-mRNA
splicing and gene expression.
Mutations that affect splicing have been shown to account
for up to half of disease-causing gene alterations (6,7). Since
longer proteins are more likely to be involved in genetic dis-
orders than shorter proteins and disease genes have, on aver-
age, a longer coding sequence and a higher number of introns
than genes not causing recognizable phenotypes, it was
hypothesized that splicing mutations may represent the
most frequent cause of hereditary disease (8). The most com-
mon outcome of mutations affecting splice sites is exon skip-
ping, followed by cryptic splice site activation (9,10). Cryptic
50 ss are more common than cryptic 30ss (9), but their unequal
prevalence has not been understood.
Cryptic 50 ss have a similar frequency distribution in exons
and introns (11). Because recognition of 30ss involves addi-
tional conserved elements in the intron (PPT and BPS), the
distribution of aberrant 30ss in exons and introns would be
expected to reﬂect a more complex sequence context of the
30ss. However, since the initial analysis of single-nucleotide
substitutions in splice junctions (10) and a survey of 15 cryptic
30ss in 1994 (9), no reliable data have been available in the
literature.
Here, we have compiled sequences of previously published
aberrant 30ss in human disease genes. Our analysis revealed a
biased distribution of cryptic 30ss generated by mutations in
the 30 YAG towards exons and de novo 30ss towards introns.
We propose that the former can be fully explained by a deple-
tion of AG dinucleotides in the PPT, while the latter is due
to a lack of pyrimidine stretches downstream of authentic 30ss.
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doi:10.1093/nar/gki811In addition, we have investigated a group of disease-causing
mutations that create AG dinucleotides in the PPT and activate
aberrant 30ss upstream of BPS. We found that they shared a
similar distance between predicted BPS and newly introduced
AGsandshowthatreductionofthisdistanceand/orthestrength
of the new PPT enhanced the expression of natural transcripts.
These results improve prediction of aberrant 30ss localization
in human disease genes and suggest that inspection of single-
nucleotide substitutions near the 30ss in their sequence
context may facilitate prediction of their splicing outcome.
MATERIALS AND METHODS
Compilation of cryptic and de novo 30ss
Publishedreportsofcrypticanddenovo30sswere identiﬁed by
searching PubMed (http://www.ncbi.nlm.nih.gov/entrez/
query.fcgi), locus speciﬁc mutation databases (http://
archive.uwcm.ac.uk/uwcm/mg/docs/oth_mut.html) and home
pages of genetics journals. The search was restricted to human
genes with sequence-veriﬁed aberrant RNA products pub-
lished before May 2005 that resulted from disease-
associated mutations or variants. In the majority of cases,
these alterations were not found in DNA samples from unaf-
fected individuals and/or showed co-segregation with affected
family members in the pedigrees. The aberrant 30ss were
manually validated by mapping the information in the litera-
ture to sequences in the Human Genome project databases.
Sequences of authentic, mutant and aberrant 30ss together with
the Shapiro–Senapathy (S&S) scores are available in Supple-
mentary Tables 1 (exonic 30ss) and 2 (intronic 30ss). The S&S
consensus matrix scores were computed using an algorithm
described previously (12,13). To assess the signiﬁcance of
score values, the non-parametric Mann–Whitney rank test was
employed as described previously (11). Sequences containing
AG dinucleotides between predicted BPS and authentic 30AG
(termed ‘intervening AGs’) were extracted from a collection
of 46807 constitutively spliced human introns (14). The num-
ber of nucleotides that preceded and followed intervening AGs
was computed using perl (http://www.activestate.com/
Products/ActivePerl/, v. 5.6.1) scripts available on request.
Splicing reporter constructs, cell culture and
transfections
Oligonucleotide primers for cloning LIPC, HEXB, FBN2, TH
and TSC2 reporter minigenes (pCR3.1; Invitrogen) are shown
in Supplementary Table 3. Site-directed mutagenesis was car-
ried out as described previously (15). All wild-type and
mutated constructs were validated by sequencing as described
previously (16). Transient transfections were performed in
12-well plates using FuGENE 6 (Roche). Human embryonic
kidney 293T cells were grown under standard conditions in
RPMI1640 supplemented with 10% (v/v) fetal calf serum
(Gibco BRL). The plating density was  10
5 cells per well
17–24 h before transfection. Medium was changed 2 h before
adding a DNA mixture prepared by combining 1.5 mlo f
FuGENE and 50 ml of serum-free medium, followed by addi-
tion of 0.5 mg puriﬁed plasmid DNA. For co-transfections,
0.5 mg of reporter DNA was mixed with 1 mg of plasmids
expressing SR proteins obtained as described previously (15).
Cells were harvested 48 h post-transfection.
Detection of mRNA products
Total RNA was extracted as described previously (15), treated
with DNase I (Ambion) and reverse transcribed using
oligo(dT)15 primers and Moloney murine virus reverse tran-
scriptase (Promega) according to the manufacturer’s recom-
mendations. Three microlitres of each cDNA reaction together
with negative and positive controls were ampliﬁed with
vector-speciﬁc PCR primers as described previously (15).
The number of PCR cycles was 29 or lower to maintain
approximately linear relationship between the RNA input
and signal. PCR products were separated on polyacrylamide
gels and stained with ethidium bromide. Transcript levels
were measured with FluorImager 595 using FluorQuant and
Phoretix software (Nonlinear Dynamics Inc.). To conﬁrm the
identity of each product, visualized fragments were extracted
from the gels and sequenced as described previously (16).
RESULTS
Biased distribution of cryptic and de novo 30ss
To maintain previous categorization of aberrant splice sites
(11), cryptic 30ss are deﬁned as those that are only used when a
mutation disrupts use of the 30ss consensus YAG. In contrast,
the term de novo refers here to all aberrant 30ss that were
induced by mutations elsewhere than in the 30YAG
(Table 1). They include newly formed 30ss AGs that are
used instead of the natural one, or result from mutations
that improve BPS, PPT or auxiliary splicing signals of the
new 30ss. For simplicity, a small number of aberrant 30ss
upstream of BPS that was generated by AG-creating mutations
in the PPT were also included in the latter category, although
these mutations do not improve the intrinsic strength of the
new 30ss,butinstead interferewith thecorrectutilizationofthe
natural site.
Compilation of previously published human aberrant 30ss
that were determined by sequencing mutated transcripts iden-
tiﬁed 147 cryptic and de novo sites in 89 genes (80 in exons
and 67 in introns; Tables 1–3). A total of 77 cryptic 30ss were
activatedasaresultofpointmutationsinthe30 YAG(Table1).
Thirty-eight point mutations were in intron position –1, posi-
tion –2 was mutated in 33 cases and position –3 in 6 cases.
Cryptic 30ss were more frequent in exons (n ¼ 59; P < 10
 4)
than in introns. Three mutations produced cryptic 30ss both in
introns and in exons (17–19). Distribution of distances
between authentic and cryptic 30ss (Figure 1A) showed that
49ofthe59(83%)exoniccryptic30sswerelocatedwithin21nt
just downstream of the intron–exon boundaries. The region of
the same size upstream of 30ss, which corresponds to an
experimentally determined optimal distance between the
branch point (BP) adenosine and 30ss (20), is depleted of
AG dinucleotides in several species, including humans
(21,22). When cryptic 30ss between authentic 30AG and
position +21 in the downstream exon were disregarded, the
distribution of the remaining cryptic 30ss was no longer
biased towards exons and resembled normal distribution
(Figure 1B).
Seventy 30ss resulted from mutations outside the 30 YAG
consensus (Table 1). Most of them were in introns (n ¼ 48;
P < 0.005), with 41 of the 48 (85%) located within 25 nt
upstream of the authentic 30ss (Figure 1C). The majority
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catalytic step were preceded by a strong PPT, although
there were several exceptions (23–26). In addition to a
major frequency peak at  19 nt upstream of the authentic
30ss, a second small peak was observed  58 nt downstream
of authentic 30ss (Figure 1C and Table 1), but the number
of these 30ss was low. The second peak is likely to result
from a depletion of de novo sites in the ﬁrst  25 nt of the
exon, rather than to their absolute over-representation further
downstream. Such depletion could be due to interference
by complexes assembled at the authentic 30ss, selection
against codons carrying AGs in the 50 end of internal exons
(27) or a lack of suitable BP adenosine within an optimal
distance from de novo 30ss.
Although intronic de novo 30ss were almost exclusively
generated by AG-creating mutations, such mutations con-
tributed much less to the formation of exonic de novo 30ss.
Apart from three examples of direct AG creation in exons
(28–30), three de novo sites were produced by point mutations
in position –3 (31–33), one in position –5 (34) and three in
position –6 (35–37) relative to the new intron–exon junction.
Three aberrant exonic 30ss resulted from mutations of the
predicted BP adenosine (38,39) or conserved uridine in
position –2 relative to BP (40), known hot-spots of single-
nucleotide substitutions in the human BPS (15). Several
aberrant 30ss in exons resulted from more distant mutations
(39,41), highlighting the importance of PPT, BPS and distant
auxiliary splicing signals for the activation of 30ss in this
category. Together, these results indicated that, in contrast
to cryptic 30ss, distribution of de novo acceptors was biased
towards introns, particularly towards the PPT. Unlike intronic
30ss, which largely resulted from AG-creating mutations,
de novo 30ss in exons were commonly generated by mutations
elsewhere than in the 30YAG of the new intron–exon
boundary.
Sequence alignments of aberrant 30ss in each category
(Figure 2A–D) revealed a higher purine content for cryptic
30ss in exons (Figure 2A) as compared with all human 30ss (42)
or corresponding authentic 30ss (Figure 2E). Adenosine in
position –3 was over-represented among exonic cryptic 30ss
(Figure 2A), possibly just reﬂecting higher levels of purine
residues in the sequences surrounding the new intron–exon
junction. The number of aberrant 30ss in the next two cate-
gories (Figure 2B and C) was low. Intronic de novo 30ss
(Figure 2D) had frequent uridine in position +1 of the new
exon as well as pyrimidines in position  4 of the new intron.
Finally, purine depletion observed for aberrant 30ss in the new
PPT was in similar PPT positions as in authentic 30ss
(Figure 2E) or all 30ss invertebrates (42).This points to similar
requirements for interactions with poly(Y) binding proteins,
such as the large subunit of U2 auxiliary factor (U2AF
65), and
is consistent with frequent manifestation of splicing pheno-
types as a result of mutations or naturally occurring DNA
variants in these PPT positions (15,43–47).
The median distance between authentic and aberrant 30ss
was 2 nt (Table 1, each distance is shown in Supplementary
Tables 1 and 2), while the absolute median distance was 16 nt.
The median distances from authentic sites to exonic cryptic
30ss or intronic de novo 30ss were similar (12 nt; Figure 1 and
Table 1). The median distances between intronic cryptic 30ss
and exonic de novo sites were also comparable (Table 1).
Occasionally, mutations activated a cryptic 30ss in an exon
further downstream, up to 1165 nt from the mutation (48).
In this extreme case, the authentic 30ss was preceded by a
very strong PPT, separating the 30ss and the ﬁrst upstream
adenosine by 64 nt (or a predicted distant BP by 68 nt),
Table 1. Summary of aberrant 30 splice sites in human genes









Number of genes 39 16 14 35 89
Number of cryptic/de novo 30ss
(% in exons and introns)
59 (74) 21 (26) 18 (27) 49 (73) 147
Number of unique 30ss (%) 56 (75) 19 (25) 18 (27) 48 (73) 141
Reading frame
0 18 7 5 19 49 (33.3%)
+1 23 5 8 15 51 (34.7%)
+2 18 9 5 15 47 (32.0%)
Average distance (nt) between
authentic and cryptic 30ss (SD)
43.8 (46.4)
b 57.9 (29.9)  71.6 (120.3)  19.1 (33.7) 10.7 (67.2)
b
Median distance (nt) between
authentic and cryptic 30ss
12 54  44  12 2
Number of terminal exons (%) 10 (17) 2 (10) 6 (33) 3 (6) 21 (14)
Average S&S score (SD)
Authentic (A) 85.3 (6.1) 80.8 (10.0) 87.6 (4.9) 81.3 (6.6) 83.6 (7.2)
Mutated (M) 68.4 (8.0) 80.2 (9.7) 72.3 (5.3) 78.8 (8.4) 74.1 (9.5)
Cryptic/de novo (CR) 74.2 (8.2) 82.3 (7.6) 83.8 (6.0) 77.6 (7.9) 77.7 (8.5)
Average difference
a
A-M (P-value) 16.9 (2 · 10
 17) 0.9 (N.S.) 15.1 (9 · 10
 10) 2.5 (N.S.) 9.6 (10
 18)
M-CR (P-value) 5.7 (3 · 10
 4) 2.0 (N.S.) 11.4 (10
 16)  1.2 (N.S.)  3.6 (6 · 10
 4)
A-CR (P-value) 11.2 (10
 18)  1.2 (N.S.) 3.8 (0.07) 3.7 (0.04) 6.0 (10
 19)
aMann–Whitney rank test (SPSS, SPSS Inc., USA).
bExcluding an outlier of 1165 nt (48).
SD, standard deviation; NS, not statistically significant.
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Gene Phenotype Mutation Location of cryptic 30ss Reference
ABCR (ABCA4) Stargardt disease E16+1G>C E16+3 (31)
ACAT1 Mitochondrial acetoacetyl-CoA thiolase deficiency E5+46C>T E5+51 (35)
ALG8 Glycosylation deficiency IVS1-2A>G E2+11 (96)
ARSA Metachromatic leukodystrophy E8+22C>T E8+27 (37)
ASS Citrullinaemia IVS14-1G>C E15+7 (97,98)
ATM Ataxia telangiectasia IVS38-2A>C E39+61 (6)
ATM Ataxia telangiectasia IVS64-1G>C E65+13 (6)
BRCA2 Breast cancer IVS23-2A>G E24+7 (99)
BTD Biotinidase deficiency E1+56G>A E1+57 (30)
CBFA2 (RUNX1) Familial thrombocytopenia IVS20-1G>T E21+13 (100)
CDKL5 Rett syndrome IVS13-1G>A E14+1 (101)
CLN3 Batten disease IVS15-1G>T E16+5 (102)
COH1 Cohen syndrome IVS51-1G>T E52+16 (103)
COL17A1 Epidermolysis bullosa IVS31-1G>T E32+9 (17)
COL17A1 Epidermolysis bullosa simplex IVS21-2A>C E22+27 (104)
COL1A2 Ehlers-Danlos syndrome type VII IVS5-1G>C E6+15 (105)
COL1A2 Osteogenesis imperfecta IVS27-2A>G E28+46 (106)
COL2A1 Stickler syndrome IVS17-2A>G E18+16 (107)
COL5A1 Ehlers-Danlos syndrome type I IVS4-2A>G E5+12, E5+15 (108)
DAF CD55 deficiency E5+18C>T E5+44 (40)
DMD Dystrophinopathy IVS20-2A>G E21+7 (109)
DMD Muscular dystrophy IVS74-2A>G E76+60 (48)
EPB42 Recessive hereditary spherocytosis E11+39G>T E11+41 (33)
F8 Haemophilia A E11+32G>T E11+36 (34)
F8 Haemophilia A E16+26G>A E16+47 (38)
F8 Haemophilia A IVS15+1G>T E16+47 (50)
FGB Hypofibrinogenaemia E4+115T>A E4+116 (28)
G6PC Glycogen storage disease type 1a E5+86G>T E5+91 (36)
G6PD Glucose-6-phosphate dehydrogenase deficiency IVS10-2A>G E11+9 (110)
GH-1 Growth hormone deficiency IVS3del28-45 E3+98 (111)
GLA Fabry disease IVS3-1G>A E4+1 (112)
GLA Fabry disease IVS6-1G>A E7+1 (113)
GPB Henshaw antigen E5+65C>G E5+65 (114)
HEXB Sandhoff disease E11+8C>T E11+112 (49)
HEXB Sandhoff disease IVS10-17A>G E11+112 (19)
HLA-B*3916 Deficient expression of HLA-B E3+17G>C E3+19 (32)
HPRT1 Hypoxanthine–guanine phosphoribosyltransferase deficiency IVS1-2A>G E2+5 (115)
HPRT1 Hypoxanthine–guanine phosphoribosyltransferase deficiency IVS5-1G>A E6+1 (115)
HPRT1 Hypoxanthine–guanine phosphoribosyltransferase deficiency IVS7-1G>A E8+21 (115)
HPRT1 Hypoxanthine–guanine phosphoribosyltransferase deficiency IVS9-1G>A E10+17 (116)
HPRT1 Hypoxanthine–guanine phosphoribosyltransferase deficiency IVS9-2A>G E10+17 (117,118)
HPRT1 Hypoxanthine–guanine phosphoribosyltransferase deficiency IVS9-2A>T E10+17 (117,118)
INSR Rabson-Mendenhall’s syndrome IVS4-2A>G E5+12 (119)
ITGA2B Glanzmann thrombasthenia IVS3-3DEL13 E4+18 (120)
ITGB4 Epidermolysis bullosa IVS31-19T>A E32+38 (41)
KRT14 Recessive epidermolysis bullosa simplex IVS2-2A>C E3+10 (121)
LAMA2 Muscular dystrophy IVS28-1G>C E29+69 (122)
LAMC2 Junctional epidermolysis bullosa IVS3-1G>A E3+2 (123)
LDLR Familial hypercholesterolaemia IVS1-1G>C E2+10 (124)
LDLR Familial hypercholesterolaemia IVS7-1G>C E8+17 (125)
LDLR Familial hypercholesterolaemia IVS9-1G>A E10+7 (126)
LDLR Familial hypercholesterolaemia IVS9-30 GTGCTGATG>CGGCT E10+54 (127)
LHX4 Syndromic short stature IVS4-1G>C E5+12, E5+20 (128)
MANBA Beta-mannosidosis IVS15-2A>G E16+172 (81)
NF1 Neurofibromatosis type 1 IVS27b-2A>T E28+293 (80)
NIS (SLC5A5) Congenital hypothyroidism E13+67C>G E13+67 (29)
OAS1 Oligoadenylate synthase activity IVS6-1A>G E7+1, E7+137 (129)
OTC Ornithine transcarbamylase deficiency IVS4-2A>T E5+12 (130)
PDE6B Autosomal recessive retinitis pigmentosa IVS2-1G>T E3+12 (131)
PFKM Muscle phosphofructokinase deficiency IVS6-2A>C E7+5, E7+12 (132)
PKLR Pyruvate kinase deficiency IVS3-2A>T E4+6 (133)
PTPS Pyruvoyl-tetrahydropterin synthase deficiency IVS1-3C>G E2+12 (134)
SCNN1G Pseudohypoaldosteronism type 1 IVS2-1G>A E3+6 (135)
SPG4 Spastic paraplegia IVS6-1G>A E7+8 (136)
SPINK5 Netherton syndrome IVS20-1G>A E21+1 (137)
TNFSF5 (HIGM1) X-linked hyper-IgM syndrome IVS4-2A>G E5+8 (138)
TP53 Li-Fraumeni syndrome IVS3-1G>A E4+19 (139,140)
TP53 Li-Fraumeni syndrome IVS5-11DEL11 E6+17 (141)
TP53 Li-Fraumeni syndrome IVS5-1G>A E6+1 (139)
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long distance from authentic 30ss. We also found that several
identical aberrant 30ss in exons were activated by distinct
mutations, such as HEXB E11+112 by E11+8C>T and
IVS10-17A>G (19,49), or F8 E16+47 by a mutation at
IVS15-1 and an exon 16 mutation (38,50) (Table 2), providing
clear evidence that mutations in very diverse positions may
result in the same splicing defect.
As with the cryptic 50 ss (11), neither cryptic nor de novo
30ss showed any bias towards a particular reading-frame phase
relative to the position of authentic 30ss (Table 1). This may
reﬂect only a partial elimination of mRNAs with premature
termination codons by nonsense-mediated mRNA decay or
even a complete unresponsiveness of mutated transcripts to
RNA surveillance mechanisms, as reported for HBB (51).
Finally, similar to the cryptic 50 ss (11), pair-wise compar-
isons of the average S&S matrix scores for authentic 30 ss and
their mutated and cryptic counterparts showed signiﬁcant dif-
ferences, with the identical A>CR>M score hierarchy for both
exonic and intronic cryptic 30 ss (Table 1 and Supplementary
Tables 1 and 2). In contrast, the average S&S matrix scores for
de novo 30 ss were not signiﬁcantly higher than corresponding
mutated sites and were not lower than corresponding authentic
30 ss, except for a borderline signiﬁcance of intronic de novo
30 ss (Table 1). Thus, the predictive value of the S&S
matrix scores was evident only for cryptic, but not for
de novo 30ss.
AG-creating mutations in the PPT that suppress
authentic 30ss and activate aberrant 30ss:
a role for ‘BPS-new AG’ distance
The majority of AG-creating mutations in the PPT that
resulted in the activation of aberrant 30ss used the newly intro-
duced AGs in the second step of splicing (Figure 1C). How-
ever, there were several exceptions. Newly created AGs in
LIPC (52), HEXB (19) and AR (23) were not efﬁciently used
for exon ligation, but led to the activation of aberrant 30ss
upstream of putative BPS, while suppressing authentic 30ss.
A similar repression of authentic 30ss was observed for FBN2,
where the introduction of AG, which was not used in the
catalytic step in vivo, resulted in exon skipping (53). In this
small group of mutations, recognition of new AGs was sufﬁ-
cient to suppress utilization of authentic 30ss, but was insuf-
ﬁcient for exon joining. Sequence inspection of these cases
revealed that even though the distance between newly created
AGs and authentic 30ss was variable, the distance between
predicted BPS and the mutation was similar, ranging from
11 to 15 nt (Figure 3A).
To investigate the distance requirements for the activation
of aberrant 30ss, we constructed three-exon splicing reporters
for LIPC, HEXB and FBN2 (Figure 3B). We refer to these 30ss
as upstream (U) and mutated (M) (Figure 3A) to avoid
ambiguous distinction between cryptic and de novo 30ss in
these cases. As each germline mutation was an A>G transition
(19,52,53), which are characteristic of BP substitutions (15),
we ﬁrst attempted to determine the BP. However, none of the
pre-mRNA substrates could be spliced in vitro with varying
concentrations of nuclear extracts and Mg
2+ (data not shown).
As A>G substitutions in the BP impart a particularly strong
block of splicing in vitro (54) and in vivo, which may facilitate
BP determination (J. Kra ´lovic ˇova ´, H. Lei and I. Vor ˇechovsky ´,
manuscript submitted),wemutatedthe putative BPadenosines
into G, C and T in each wild-type construct (Figure 3C).
Examination of RNA products after transfection showed
that only the G-containing clones led to aberrant splicing.
In FBN2, exon skipping observed in vivo in a patient with
contractural arachnodactyly (53) was replicated in 293T cells
where it was accompanied by a partial utilization of the newly
introduced AG (Figure 3C and D). In LIPC, we found two
aberrant30ss,asreportedearlier (52).Theﬁrst30sswasutilized
in  6% at the site of mutation (IVS1-13) and the other was
upstream of the predicted BPS (IVS1-78; Figure 3B, C and E).
The ratios of unspliced/-13/-78 RNA products described pre-
viously (1/2.9/0.8, respectively) (52) was altered in favour of
the upstream cryptic 30ss in our system (Figure 3C). This was
most likely due to a better BPS consensus in our construct,
because a previously used minigene (52) had intron truncation
just upstream of IVS1-78 and lacked a suitable alternative BPS
(data not shown). Finally, the HEXB transition (Figure 3A)
also activated two aberrant 30ss. One was 37 nt upstream of
exon 11 and the other was in exon 11, 112 nt downstream of
the authentic site (Figure 3B and F). We could not exclude that
IVS10-17A is the BP of the central exon as suggested earlier
(19), but improved splicing of uridine- and, to a lesser extent,
cytosine-containing pre-mRNAs (Figure 3C, middle panel)
suggested that this mutation is in the PPT since uridines are
the preferred PPT nucleotides (55,56). As LIPC and FBN2
mutations were even closer to the 30ss than the HEXB mutation
(Figure 3A), their BPs are likely to map upstream of newly
introduced AGs as well.
To test whether the aberrant 30ss were activated only by
AGs and not by other dinucleotides, we changed BP-1 ade-
nosines to guanosines in each wild-type and mutated FBN2/
LIPC minigene to create additional dinucleotides GA, GC, GT
and GG (Figure 3G). Of the eight dinucleotides (Figure 3C
and G), only AG-containing reporters maintained the splicing
defects. In LIPC, utilization of the upstream 30ss IVS1-78 was
Table 2. (Continued)
Gene Phenotype Mutation Location of cryptic 30ss Reference
TP53 Lung cancer IVS3-1G>C E4+19 (142)
TSC2 Tuberous sclerosis IVS38-18G>A E39+74 (39)
TSC2 Tuberous sclerosis IVS9-15G>A E10+56 (39)
TSC2 Tuberous sclerosis IVS9-3C>G E10+56 (39)
UGT1A1 Crigler-Najjar syndrome type 1 IVS3-2A>G E4+107 (143)
UGT1A1 Crigler-Najjar syndrome type 1 IVS4-1G>A E5+7 (144)
XPA Xeroderma pigmentosum group A IVS3-1G>C E4+2 (145)
4886 Nucleic Acids Research, 2005, Vol. 33, No. 15highest in pre-mRNAs containing guanosine -15 (IVS1-15G),
followed by those containing A or C, and was lowest for pre-
mRNAs with uridine at this position, further supporting the
PPT location of the newly formed AG. To formally show that
the predicted BPS itself can tolerate AG dinucleotides, we
employed two splicing reporters that were derived from the
TH and TSC2 genes. Both mutated minigenes represented
previously observed substitutions in the predicted BPS
that resulted in genetic disease (39,57). Substitutions of
the predicted BP adenosines to the remaining nucleotides
Table 3. Cryptic and de novo 30 splice sites in introns
Gene Phenotype Mutation Location of cryptic 30ss Reference
APOE ApoE deficiency IVS3-2A>G IVS3-52 (73)
AR Androgen insensitivity IVS2-11T>A IVS2-69 (23)
ATM Ataxia telangiectasia IVS32-12A>G IVS32-11 (6)
ATM Ataxia telangiectasia IVS16-10T>G IVS16-9 (6)
ATP7B Wilson disease IVS11-2A>G IVS11-39 (146)
BRCA1 Breast cancer IVS7-24del10 IVS7-59 (147)
BRCA1 Familial breast cancer IVS5-12A>G IVS5-11 (148)
CFTR Cystic fibrosis IVS17a-26A>G IVS17a-25 (149,150)
CHIT1 Chitotriosidase deficiency E10+20dupl24 E10+103 (151)
COL17A1 Benign epidermolysis bullosa IVS31-1G>T IVS31-69, IVS31-264 (17)
COL5A1 Ehlers-Danlos syndrome type II IVS13-2A>G IVS13-100 (94)
CPO Hereditary coproporphyria IVS1-15C>G IVS1-14 (152)
CYBB Chronic granulomatous disease IVS4-15del36 IVS4-179 (153)
CYP21B 21-hydroxylase deficiency IVS2-13C>G IVS2-19, IVS2-33 (154)
DBT Maple syrup urine disease IVS4-17TTT>AAA IVS4-17 (155)
DMD Muscular dystrophy IVS59-9T>A IVS59-7 (156)
DMD Muscular dystrophy IVS8-15A>G IVS8-14 (48)
ELN Supravalvular aortic stenosis IVS15-3C>G IVS15-44 (93)
ERCC3 Xeroderma pigmentosum IVS14-6C>A IVS14-4 (157)
FANCA Fanconi anaemia IVS15-1G>T IVS15-90 (158)
GCH1 Dystonia IVS2-2A>G IVS2-1 (159)
HBB Beta-thalassaemia IVS1-15T>G IVS1-14 (160)
HBB Beta-thalassaemia IVS1-21G>A IVS1-19 (161–163)
HBB Beta-thalassaemia IVS2-A>G IVS2-271 (74)
HEXB Sandhoff disease IVS10-17A>G IVS10-37 (19)
HEXB Sandhoff disease IVS12-26G>A IVS12-24 (24,164)
HPRT1 Hypoxanthine–guanine phosphoribosyltransferase deficiency IVS8-3T>G IVS8-2 (165)
HPRT1 Hypoxanthine–guanine phosphoribosyltransferase deficiency IVS8-16G>A IVS8-14 (165,166)
ITGB2 Leukocyte adhesion deficiency IVS6-14C>A IVS6-12 (167)
L1CAM X-linked hydrocephalus IVS17-19A>C IVS-69 (168)
L1CAM X-linked hydrocephalus, MASA syndrome, spastic paraplegia IVS26-12G>A IVS26-10 (169)
LIPC Hepatic lipase deficiency IVS1-14A>G IVS1-78, IVS1-13 (52)
MECP2 Rett syndrome IVS1-6C>G IVS1-5 (170)
MLYCD Malonyl-CoA decarboxylase deficiency IVS4-14A>G IVS4-13 (171)
MPO Myeloperoxidase deficiency IVS11-2A>C IVS11-109 (72)
MTM1 X-linked recessive myotubular myopathy IVS12-10A>G IVS12-9 (172)
MYBPC3 Hypertrophic cardiomyopathy IVS14-13G>A IVS14-11 (173)
NF1 Neurofibromatosis type I IVS15-16A>G IVS15-15 (7,25)
NF1 Neurofibromatosis type I IVS15-15A>G IVS15-14 (25)
NF1 Neurofibromatosis type I IVS10a-9T>A IVS10a-7 (7,25)
NF1 Neurofibromatosis type I IVS39-12T>A IVS39-10 (80)
NF1 Neurofibromatosis type I IVS26-2A>T IVS26-14, IVS26-17 (80)
NF1 Neurofibromatosis type I IVS11-3C>G IVS11-43 (7)
NF1 Neurofibromatosis type I IVS15-12T>G IVS15-11 (25)
OCA2 Type II oculocutaneous albinism IVS5-19A>G IVS5-18 (174)
PAH Phenylketonuria IVS8-7A>G IVS8-6 (66)
PAH Phenylketonuria IVS10-11G>A IVS10-9 (175)
RB1 Retinoblastoma IVS22-8T>A IVS22-6 (176)
SAG(S-ARRESTIN) Retinitis pigmentosa IVS10-25A>G IVS1-24 (177)
SALL1 Townes-Brocks syndrome IVS2-19T>A IVS2-17 (178)
SERPINC1 Type I antithrombin deficiency IVS4-14G>A IVS4-12 (179)
SOD1 Amyotrophic lateral sclerosis IVS4-10T>G IVS4-9 (180)
TCF1 (HCF-1A) Maturity-onset diabetes of the young IVS4-2A>G IVS4-202 (181)
TCF1 (HCF-1A) Maturity-onset diabetes of the young IVS7-6G>A IVS7-4 (181)
TH Extrapyramidal movement disorder IVS11-24T>A IVS11-36 (57)
TNFRSF1A Periodic fever syndrome IVS3-14G>A IVS3-12 (26)
TP53 Li-Fraumeni syndrome IVS9-1G>C IVS9-44 (92)
TP53 Li-Fraumeni syndrome IVS3-11C>G IVS3-10 (139)
TPMT Thiopurine methyltransferase deficiency IVS9-1G>A IVS9+1, IVS9-330 (18)
WRN Werner’s syndrome IVS29-7T>A IVS29-5 (182)
ZAP70 Severe combined immunodeficiency IVS9-11G>A IVS9-9 (183)
Nucleic Acids Research, 2005, Vol. 33, No. 15 4887in both reporters dramatically increased exon skipping
(J. Kra ´lovic ˇova ´, H. Lei and I. Vor ˇechovsky ´, manuscript sub-
mitted). Since predicted BP-As were preceded by Gs in each
intron, we mutated BP-1Gs to As in the wild-type and mutated
reporters, but the splicing pattern observed for the constructs
carrying AA, AC, AT and AG dinucleotides was similar to
those containing GA, GC, GT and GG (Figure 3H and data not
shown). Taken together, these data suggested that activation of
30ss upstream of the BPS and inhibition of authentic 30ss is
speciﬁc for AG dinucleotides in the PPT.
Reduction of the ‘BPS-new AG’ distance improves the
expression of natural transcripts
To test a role of the ‘BPS-newAG’ distance in repression and
activation of three competing 30ss, we examined the splicing
pattern of LIPC and HEXB constructs containing serial 3 nt
deletions in this region (Figure 4A–C). In addition, we modi-
ﬁed this distance in the HLA-DQB1 reporter (allele *0602),
which contains a preexisting AG dinucleotide downstream of
the BPS (Figure 4A and D) (15). The BP of DQB1 exon 4 was
determined by reverse transcription and mutagenesis (15) and
corresponded to the best match to mammalian BPS in intron 3
(Figure 4A) and to a computationally predicted BPS (14).
Figure 1. Distribution of the distances between authentic and aberrant 30ss.
(A) Cryptic splice sites resulting from mutations at the 30YAG consensus.
(B) Cryptic splice sites resulting from mutations of the 30YAG, except for
cryptic 30ss in exon positions 1–21. (C) Aberrant 30ss due to mutations outside
the30YAG(‘denovo’).TheStatastatisticalpackage(v.8.2,StataCorp,TX)was
usedtofitkerneldensityplotstothedistancesbetweenauthenticandcryptic/de
novo 30ss. Positiveandnegativenumberscorrespondto aberrant30ss locatedin
the downstream exon or the upstream intron, respectively. The number of
occurrences of aberrant 30ss is shown as short vertical bars for each distance




exons resulting from mutations of the 30 YAG; (B)3 0ss in exons due to muta-
tionsoutsidethe30 YAG;(C)cryptic30ssinintronsthatresultedfrommutations
of the 30 YAG; (D) aberrant 30ss located in introns generated by mutations
outside the 30 YAG. (E) Consensus sequences of corresponding authentic 30ss
(n ¼ 147). The relative nucleotide frequencies at each position were plotted
with a pictogram utility (http://genes.mit.edu/pictogram.html). The height of
each letter is proportional to the frequency of the corresponding base at the
given position. Arrows indicate over-representation of adenine in position  3
(A) and of uridine in position +1 (D) of the new intron or exon, respectively.
4888 Nucleic Acids Research, 2005, Vol. 33, No. 15In LIPC, deletions that reduced the distance between pre-
dicted BP and the newly created AG from 13 to 10, 7 and 4 nt,
eliminated use of the mutated site (Figure 4A and B, lanes
1–5). Three- and six-nt deletions rescued normal splicing to
16 and 89%, respectively, and progressively inhibited
upstream 30ss (lanes 3 and 4). However, the largest deletion
no longer improved splicing to the authentic 30ss (lane 5), most
likelyby reducing the gapbetween the BPandauthentic 30ssto
only 17 nt, which is below the experimentally determined
optimum of 19–23 nt (20). These results suggested that the
minimum ‘BP-new AG’ distance required for engagement of
the new AG in the catalytic step and for complete suppression
of authentic 30ss in this pre-mRNA was  13 nt. Bringing this
AG closer to the BPS was associated with a signiﬁcant pro-
duction of natural transcripts. Their increase was accompanied
by a decrease of the S&S scores for the mutated sites
(Figure 4A), suggesting that diminished recognition of the
de novo site due to reduced pyrimidine content upstream of
the mutated AG in deletion mutants weakens AG-induced
inhibition of the authentic 30 ss. Also, we could not exclude
a beneﬁcial effect of a reduced ‘BP-authentic AG’ distance on
the expression of natural transcripts.
In HEXB, splicing to the authentic 30ss was rescued only by
the largest deletion, which decreased the ‘BP-new AG’ dis-
tance from 15 to 6 nt (Figure 4C). Reduction of the S&S score
for the mutated 30 ss in this deletion mutant was associated
with increased use of authentic sites and decreased use of 30 ss
E+112. In DQB1, a preexisting AG is located 7 nt downstream
of the BP adenosine (Figure 4A) and is not used in the second
splicing step (15). Insertion of ﬁve uridine residues in front of
the 30ss CAG consensus to reach a BP-AG distance compa-
rable with the remaining reporters (Figure 3A) was sufﬁcient
for  9% utilization of this AG (Figure 4D, lane 2). The new
30ss (Figure 4E) was markedly promoted further by extending
the new PPT to (T)10 with a concomitant improvement of exon
inclusion, both in the presence (alleles DQB1*02-05) and
absence (DQB1*06) of a polymorphic guanosine in position
-14 (Figure 4A and D, lanes 3 and 6). Together, these results
showed that moving the newly created AG closer to the BP
while maintaining the distance between authentic and new
AGs promoted selection of the authentic 30ss. They also sug-
gested that AG-creating mutations located closer to the BPS
Figure3.AG-creatingmutationsinthePPTthatactivateaberrant30ssupstream
of predictedBPS.(A) Aberrant30ss activatedby newly createdAGs(in italics)
that repress (minus sign) authentic 30ss in the PPT (upper panel). Distances
between upstream 30ss (U) and predicted BP, between newly created AG
(mutated, M) and BP (arrow) and between the mutated and authentic (A)
30ss are in base pairs, bp (lower panel). The S&S scores were computed for
U, M and A 30ss using an algorithm as described previously (12,13). BPS is
shown as a black rectangle. Disease-causing mutations were LIPC IVS1-
14A>G (52), HEXB IVS10-17A>G (19), AR IVS2-11T>A (23) and FBN2
IVS28-15A>G(53).PutativeBPSswereGGCTAAG,GCCTAAT,TATCAAC
and TGACAAT, respectively. (B) Schematic representation of minigene con-
structs. Exons are shown to scale (scale unit is 0.1 kb). The sizes of minigene
introns (lines; not to scale) are shown below each construct. Intron truncations
are indicated by a slash. Full LIPC introns 1 and 2 were 106.2 and 3.3 kb,
respectively. Allele-specific DQB1 minigenes were described previously (15).
(C) Splicing pattern of mutated minigenes after transfection into 293T cells.
RT–PCR products amplified with vector-specific primers PL3 and PL4. Wild-
typeminigenescontainingpredictedBPadenineintheindicatedpositionswere
mutated to C, T and G. RNA species were confirmed by sequencing and are




30ss in mutated constructs. Exons (e) are indicated by grey rectangles, introns
(IVS, intervening sequence) by a white rectangle. Aberrant 30ss are designated
by a distance from the corresponding authentic splice site. (G) Activation of
aberrant splice sites is specific for AG dinucleotides. Mutations removing AG
dinucleotides are indicated at the top and bottom of each panel. (H) AG di-
nucleotideswithinpredictedBPSdonotactivatecrypticsplicesites.Mutations
creating AG dinucleotides in the predicted BPS are indicated at the top and
bottom of each panel.
Nucleic Acids Research, 2005, Vol. 33, No. 15 4889and/or preceded by weaker PPTs may have less severe pheno-
typic consequences and provided support to the model
that proposes a substrate-speciﬁc area of exclusion of AG
dinucleotides downstream of the BP.
Prevalence and sequence context of intervening AG
dinucleotides in authentic and aberrant 30ss
The mutated AG was preceded by the pyrimidine and followed
by the uridine in each case (Figure 3A). The occurrence of
pyrimidines in the former position suggested that, similar to
AGs in authentic 30ss, cytosines and uridines may facilitate
partial recognition of intervening AG dinucleotides. However,
the presence of uridines that immediately followed each of
these AGs was conspicuous, because uridine is the least
frequent nucleotide in humans, mouse, zebraﬁsh and fugu
in this position (42). This could simply reﬂect a higher uridine
content in the surrounding sequence (cf. Figures 2D and E);
nevertheless, we analysed the effect of T>G alterations in this
position on LIPC and DQB1 splicing. The LIPC IVS1-13T>G
mutation, which improved a match to the 30ss YAG/R, com-
pletely eliminated utilization of this site and promoted the
upstream 30ss (Figure 4B, lane 6). In contrast, an insertion
of a polymorphic guanosine in position –14 of DQB1 intron
3 further promoted the new 30ss (Figure 4D, lanes 2 and 5).
AGs between BPS and authentic 30AG are rare (21), but
they are more common near the BPS (14) or closer to the 30ss,
often as ‘tandem’ (NAGNAG) acceptors (58) that effectively
compete with each other. Inspection of 147 aberrant 30ss
revealed 15 (10%; 11 in exons, 4 in introns) intervening
AGs in a 14 nt sequence upstream of authentic 30ss (Supple-
mentary Tables 1 and 2). In contrast, corresponding authentic
30ss had only four AGs in this region (P < 0.01; Fisher exact
test), suggesting that intervening AGs are more common in
aberrant than in authentic 30ss.
Use of 30AG in splicing is inﬂuenced by the identity of the
preceding nucleotide, with a hierarchy of competitiveness
CAG   UAG > AAG > GAG (59,60). We analysed the
Figure 4. Aroleforthe BPS-newAGdistanceand/orthestrengthofthenewPPTinupstreamcryptic30ssactivation.(A) Nucleotidesequencesofsplicingreporter
constructs at the 30ss are followed by the S&S matrix scores and by the percentage of splice site utilization of the indicated RNA products (means of duplicate
transfections). Intronic sequences are in lower case, exonic sequences are in upper case. Putative BPs are shaded. U, aberrant 30ss upstream of predicted BPS; M,
newlycreated(preexistinginDQB1)orproximalAGbetweentheauthentic30ssandBP;A,authenticordistal30ss.ES,exonskipping;+112,%utilizationofthesplice
site+112bytheHEXBpre-mRNAssite.TheS&Sscoreswerecalculatedaccordingtothealgorithmdescribedpreviously(12,13).BPSsofLIPCexon2andofDQB1
exon 4 were predicted by a branch site tool (http://ast.bioinfo.tau.ac.il/), with BPS scores 3.25 and 3.2, respectively. No BPS was predicted for HEXB. The HEXB
IVS10-29A>GandIVS10-29A>Tgavesplicingpatternsidenticaltothewild-typeconstructs(datanotshown).RT–PCRproductsfortheLIPC-14YandHEXB-17Y
mutationsareshowninFigure3C.(B–D)RNAproductsgeneratedbywild-typeandmutatedconstructsaftertransfectioninto293Tcells.Thedesignationofsplicing
reporter constructs (top of each panel) corresponds to that in (A). RNA products were confirmed by sequencing and are schematically shown on the right side. (E)
Nucleotide sequences of RT–PCR products illustrating aberrant splice sites in DQB1 reporters.
4890 Nucleic Acids Research, 2005, Vol. 33, No. 15frequency of each nucleotide that precedes intervening AGs as
a function of distance from the BPs predicted through com-
parison of mouse and human introns (14). To maximize the
probability of studying functional BPSs, we limited our anal-
ysis to 40388 human introns, in which predicted BPs were
located within a 40 nt distance from authentic 30ss. Interest-
ingly, cytosines were consistently over-represented in each
position between 3 and  21 nt downstream of the predicted
BP adenosine (Figure 5A). A frequency peak in position 3
apparently reﬂects over-representation of cytosines in the last
nucleotide of predicted BPS (YNCURAY+1A+2G+3). The rel-
ative nucleotide frequencies varied little around 40% for
cytosines and 20% for the remaining nucleotides along the
whole distance. An exception was position 8 and 9 down-
stream of BP adenosine where purine depletion was even
greater (Figure 5A). The non-random distribution of
nucleotides that preceded intervening AGs (P < 10
 15 for
positions 4–21) is consistent with the presence of splicing
complexes covering this region and appears to support func-
tionality of most predicted BPSs, although their average dis-
tance from authentic 30ss (14) is longer than an experimentally
determined optimum (20,61).
Among nucleotides that followed intervening AGs, pyrim-
idines were consistently over-represented in positions 4–28 nt
downstream of the predicted BP adenosine (Figure 5B,
P < 10
 9), in sharp contrast to authentic 30AGs. The number
of intervening AGs was low for distances more than 20 nt
downstream from the predicted BP adenosines, but 117 of the
208 (56%) AGs were followed by cytosine residues in this
region. The distribution of nucleotides that precede and follow
intervening AGs was very similar in 40626 murine introns
where the distance characterized by over-representation of
cytosines that preceded intervening AGs had the same length
(3–21 nt downstream of predicted BP adenosine; data not
shown). Over-representation of pyrimidines in position +1
was also very similar in mouse introns to that observed in
human introns (Figure 5 and data not shown). In a 14 nt
sequence upstream of aberrant 30ss, 5 of the 15 AGs were
preceded by cytosines and 10 of the 15 AGs were followed
by pyrimidines, which did not appear to be signiﬁcantly dif-
ferent from intervening AGs of authentic 30ss.
Finally, since closely spaced AG dinucleotides at the 30ss
(20,60–62) and in a splicing silencer (63) may interfere with
each other, we employed the LIPC reporter to bring the newly
created and authentic 30AGs to proximity. We introduced an
8 nt deletion just upstream of the authentic 30ss in the construct
with the new AG to shorten this distance to just 5 nt while
maintaining the BP-30ss length within the previously deter-
mined optimum (20). The 5 nt distance was still sufﬁcient for
an interplay between closely spaced AGs (20,61,63). The 8 nt
deletion repressed utilization of both competing AGs and
resulted in exclusive splicing to upstream 30ss (Figure 4B,
lane 7). As with DQB1 (Figure 4A and D), a small insertion
of repetitive uridines between the BP and the newly created
AG rescued splicing to this AG in the presence of the 8 nt
deletion (Figure 4B, lane 8). However, this AG was used
slightly less than for the -14A>G mutation, despite more
optimal BP-AG distance and better PPT of the new exon,
supporting a strong interference by the authentic 30AG
(Figure 4A and B, lanes 2 and 8).
The influence of SR proteins on utilization of
aberrant 30 and 50 ss in LIPC
To illustrate the effect of known regulators of splicing on
cryptic 30ss utilization, we co-expressed the wild-type and
mutated (IVS1-14A>G) LIPC reporter with SR proteins
(Figure 6A). The co-transfection experiments revealed activa-
tion of two more aberrant splice sites (designated e2-24 and
IVS2-94, Figure 6B) of the second minigene intron. In both
mutated and wild-type reporters, activation of proximal 30ss
(IVS2-94) and distal 50 ss (e2-24) was promoted by ASF/SF2
and SRp40. Since the IVS2-94 splice site has a very strong
PPT and is separated from the authentic 50 ss by only 61 nt,
activationofthe distal 50 ss inexon2may beduetorestrictions
on minimum intron size. A subset of SR proteins also pro-
moted the use of upstream 30ss IVS1-78 in both the wild-type
and mutated minigenes and reduced the amount of correctly
spliced products and those spliced to the mutated site IVS1-14
(Figure 6A). These results conﬁrm that SR proteins may pro-
mote selection of proximal splice sites as described (15,64,65)
and suggest that the observed activation of atypical distal 50 ss
can be explained by intronic length constraints.
Figure 5. Sequence context of intervening AG dinucleotides in authentic 30ss.
Relativefrequenciesofnucleotidesthatimmediatelyprecede(A) orfollow(B)
AGs located 2–30 nt downstream of predicted BP adenosines. Corresponding
numbersofinterveningAGsareshownasgreycolumns.Distancesbetweenthe
predicted BP adenosine and downstream AG are in nucleotides (nt) as follows:
2 nt (YNCURAA+1G+2; BP is underlined), 3 nt (YNCURAY+1A+2G+3), 4 nt
(YNCURAY+1N+2A+3G+4), etc., up to 30.
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In this study, we have undertaken the largest compilation of
aberrant 30ss in human disease genes to date. Although cryptic
30ss are less frequent than cryptic 50 ss (9), the size of the
compileddatasetwascomparable withthatanalysed earlier for
cryptic 50 ss (11). The overall number of aberrant 30ss was
marginally higher in exons than in introns (Table 1), but
reportsofAG-creatingPPTmutations,inwhichRNAproducts
were not sequenced and were thus not included in our study,
appear to be more frequent in the literature (66–71) than those
in exons. This suggests that aberrant 30ss described in the
literature are distributed in exons and introns with approxi-
mately equal frequencies, consistent with the observed low
median distance between all aberrant and authentic 30ss
(Table 1). In contrast, if a mutation affects 30YAG, cryptic
30ss are  3 times more likely to occur in exons than in introns.
Conversely, aberrant 30ss due to mutations outside 30YAG are
 3 times more frequent in introns than in exons. The relative
intronic depletion of the former can be accounted for by a
lower prior probability of ﬁnding an alternative 30AG in the
PPT (Figure 1A and B), whereas intronic over-representation
of the latter is due to a better 30ss consensus created in the
pyrimidine-rich sequence. Sequence constraints that limit the
number of cryptic and de novo 30ss also explain a lower total
number of aberrant 30ss in the literature as compared with
aberrant 50 ss. However, since recognition sequences at the
30 ss (YAG, PPT and BPS) are more complex than at the 50ss
and spreadover alongerand morevariable distance,mutations
affecting30ssmayhavemultipleeffects thatmakeitdifﬁcultto
categorize cryptic or de novo sites unambiguously. For exam-
ple, apart from a direct AG creation in the PPT, pyrimidine to
purine substitutions may weaken the PPT of authentic 30ss and
thus contribute to their repression. Similarly, mutations of the
30 YAG (such as IVS-1G>A, Supplementary Table 4) may
potentially improve a match to the BPS consensus and pro-
mote cryptic 30ss activation in the downstream exon if a suit-
able YAG is available within an optimal distance from the
newly created BPS. We cannot entirely exclude that this can
contribute to the observed bias (Figure 1A and C); neverthe-
less, it is likely that their distribution can be fully explained by
a lack of AGs and pyrimidine residues upstream and down-
stream of authentic 30ss, respectively.
Although the number of reported cryptic 30ss in introns was
low (n ¼ 18), their proportion in terminal introns (33%)
(7,18,72–74) appeared to be higher than in other categories
of aberrant 30ss (Table 1), pointing to possible involvement of
30 end processing factors. Two de novo 30ss observed in ter-
minal exons were due to a transversion (36) and transition (37)
in position –6 of the new intron creating uridine residues that
improve PPT recognition. Purines are greatly underrepre-
sented in this PPT position in several species (42) and both
transitions and transversions of uridine –6 have been shown to
increase exon skipping and/or retention of weakly spliced
introns (15,46). These splicing defects are likely to result
from diminished interaction of the PPT with the ﬁrst RNA
recognition motif of U2AF
65 (75), which has been shown to
promote 30 end processing (76,77).
The exact mechanism by which the 30ss is recognized is not
well understood. Although the ﬁrst AG downstream from the
BPS is usually selected for exon ligation, it is unclear why it is
sometimes not the case and how exactly this is achieved. A
‘scanning mechanism’ of 30ss selection (59,60) postulated a
unidirectional, linear search that initiates at the BPS and con-
tinues until a suitable AG is selected. This model is consistent
withblockingthe second stepon the hairpinstructures inserted
between BP and 30AG (60,78). However, closely spaced, tan-
demly arranged AGs can efﬁciently compete when placed
13–22 nt downstream of the Saccharomyces cerevisiae
branchpoint (61) and 15–23 nt in a metazoan substrate (20),
although not when placed at least 35 nt from a mammalian BP
(78). Frequent cryptic 30ss in exons would support the scan-
ning model (79), but our ﬁnding that cryptic 30ss cluster in
 20 nt region just downstream of authentic 30ss (Figure 1A)
provides no support per se for this concept since their under-
representation in introns can be explained by AG depletion in
the PPT. Several distant exonic cryptic 30ss, such as NF1
E28+293 (293 nt from the start of exon 28) activated by
the IVS27b-2A>T mutation (80) or MANBA E16+172 induced
by the IVS15-2A>G transition (81), had a strong 30ss upstream
of mutated 30AGs, but they were not used despite being much
closer to the BPS than exonic cryptic 30ss. These cases raise a
speculation that exons could ﬁrst be scanned for downstream
AGs to completion before AGs upstream of authentic 30ss are
considered. The concomitant activation of cryptic 30ss
(Figure 3B and C) or 50 ss (82) in both the intron and the
exon indicates that inactivation of genuine splice sites even-
tually triggers a search for the most suitable splice sites in both
directions, consistent with a general ﬁnding that more distant
AGs compete less efﬁciently (Figure 1).
Using well-documented cases of AG-creating mutations in
the PPT that repress authentic 30ss and activate aberrant 30ss
upstream of BPS, we have illustrated the importance of the
Figure 6. The influence of SR proteins on utilization of aberrant 30 and 50 ss in
LIPC.( A) Wild-type and mutated splicing reporters were co-transfected with
plasmids expressing the indicated SR proteins. Splicing reporters are shown at
the top and SR proteins are indicated at the bottom. VO, vector only control, in
whichanemptypCGvectorwasco-transfectedwiththewild-typeandmutated
reporter constructs; NC, no co-transfection (reporter only) control. The corre-
spondingLIPC isoformsare shownon the rightside. (B) Nucleotide sequences
surroundingaberrantsplicesitesinducedbySRproteins.Exons(e)areshownas
a grey rectangle, introns (IVS) are indicated by white rectangles.
4892 Nucleic Acids Research, 2005, Vol. 33, No. 15‘BPS-new AG’ distance and/or the strength of the new PPT for
the expression of correctly spliced mRNAs. Interestingly, this
distance (Figure 3A) was similar to that reported previously
for AGs that were outcompeted by a downstream AG (62,83)
and is consistent with steric interference with a factor(s) bound
to this region. Newly created AGs are likely to recruit spliceo-
some components that compete for interactions with authentic
30ss, are partially recognized by essential splicing factors, such
as U2 snRNP (84), but may not assemble fully functional
splicing complexes (83,85). Utilization of such competing
AGs has been shown to be affected by hSlu7 (83) and
SPF45 (86). Future studies should examine interactions of
human homologues of yeast Prp18 and Prp22 with the reporter
pre-mRNAs described here, since these proteins are required
only as the BP-AG distance increases (87,88). Unexpected
promotion of upstream 30ss observed for the LIPC -14G/-
13G construct (Figure 4B, lane 6) might be addressed by
examining contacts between the ﬁrst nucleotide of the new
exon and U2AF
35 (89), U5 snRNA (90) or PRP8 (91).
As with cryptic 50 ss (11), the average S&S scores of cryptic
30ss were signiﬁcantly lower than for corresponding authentic
30ss and higher than for mutated sites (Table 1). This indicates
that intrinsic differences in the consensus 30ss sequences con-
tribute to the cryptic 30ss remaining completely silent in the
presence of a wild-type authentic site. How such cryptic 30ss
are efﬁciently inhibited is poorly understood, but nucleotides
that precede AGs and similar AG-AG measuring mechanisms
may also play an important and more general role in auxiliary
splicing sequences (63). In contrast to cryptic 30ss, the S&S
scoresofdenovosites were similartoauthenticsites (Table 1),
suggesting that they lack a predictive value in these cases. To
explore the signiﬁcance of S&S scores in selection of cryptic
30ss in exon versus intron, we paired S&S scores of intronic
cryptic 30ss with the best match to the 30ss in adjacent exons
(Supplementary Table 5), and vice versa (Supplementary
Table 6). Each intronic cryptic 30ss had a higher S&S score
than the best corresponding exonic YAG (Supplementary
Table 5). The average difference between intronic cryptic
30ss and the best match to 30ss in exons was high (14.0;
S&Si ¼ 83.8 versus S&Sbe ¼ 69.8; where i stands for intron
and be is the best S&S score in adjacent downstream exons).
Several exons lacked the YAG consensus altogether, such as
exon 10 of TP53 (92), APOE exon 4 (73) and ELN exon 16
(93), or were very short, such as 27 nt exon 32 of COL17A1
(17) or 57 nt exon 14 of COL5A1 (94), and likely to be poorly
deﬁned (95). In contrast, as much as  45% of the putative 30 ss
in an adjacent intronic sequence had S&S scores higher than
the corresponding cryptic 30ss in exons (average S&Se ¼ 73.8
versus S&Sbi ¼ 71.1; where e is exon and bi are the best
scores in a 100 nt of the upstream intron), with the average
difference only 2.7. The high differential between the S&S
scores for intronic cryptic 30ss and their putative exon coun-
terparts, which apparently reﬂects a lack of Y-runs in exons,
should be considered when using this and other algorithms for
prediction of competing 30ss.
In summary, our results improve prediction of aberrant 30ss
localization in human disease genes and provide a valuable
resource for studying the mechanisms of 30ss selection. They
also suggest that inspection of genetic alterations in or near the
30ss in their sequence context may in some cases facilitate
prediction of their splicing and phenotypic outcomes.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at NAR Online.
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